EGFR and colorectal carcinoma: The key signaling pathways alteration was seen in the EGFR/RAS/BRAF signaling pathway (74.4% (n = 1826) of CRC patients), followed by AKT/mTOR (39.2%, n = 963) and VEGFR (16.6%, n = 408) signaling pathways.